Arvinas (ARVN) Return on Capital Employed (2018 - 2026)
Arvinas' (ARVN) quarterly Return on Capital Employed came in at 44.76% in Q1 2026, down 3327.0% year-on-year from 1.39% in Q1 2025, and down 141.21% quarter-over-quarter from 18.56% in Q4 2025.
Arvinas (ARVN) Return on Capital Employed (2018 - 2026) Analysis & Trends
Arvinas' Return on Capital Employed history runs 9 years deep, the most recent figure standing at 44.76% for Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 3327.0% year-over-year to 44.76% in Q1 2026; TTM through Mar 2026 was 44.76%, a 3327.0% decrease from a year earlier, with the FY2025 full-year figure at 15.55%, up 1029.0% from the prior year.
- Return on Capital Employed slipped to 44.76% in Q1 2026 per ARVN's latest filing, from 18.56% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 11.49% in Q1 2025 and bottomed at 44.76% in Q1 2026.
- The 5-year median for Return on Capital Employed is 27.83% (2024), against an average of 28.42%.
- Across the five-year window, Return on Capital Employed soared 2753 bps in 2025 and slumped 3327 bps in 2026, its largest moves.
- Year by year, Return on Capital Employed stood at 26.16% in 2022, then tumbled by 66 bps to 43.44% in 2023, then soared by 36 bps to 27.83% in 2024, then soared by 33 bps to 18.56% in 2025, then plunged by 141 bps to 44.76% in 2026.
- Per Business Quant, the three latest ARVN Return on Capital Employed figures stand at 44.76% (Q1 2026), 18.56% (Q4 2025), and 13.95% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Arvinas | 519.68 Mn | -95.22 Mn | - | -44.76% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -44.76% |
| Dec 31, 2025 | -18.56% |
| Sep 30, 2025 | -13.95% |
| Jun 30, 2025 | -14.87% |
| Mar 31, 2025 | -11.49% |
| Dec 31, 2024 | -27.83% |
| Sep 30, 2024 | -37.72% |
| Jun 30, 2024 | -41.27% |
| Mar 31, 2024 | -39.02% |
| Dec 31, 2023 | -43.44% |
| Sep 30, 2023 | -41.37% |
| Jun 30, 2023 | -36.73% |
| Mar 31, 2023 | -31.23% |
| Dec 31, 2022 | -26.16% |
| Sep 30, 2022 | -20.89% |
| Jun 30, 2022 | -18.05% |
| Mar 31, 2022 | -15.76% |
| Dec 31, 2021 | -14.15% |
| Sep 30, 2021 | -19.12% |
| Jun 30, 2021 | -26.49% |